thyroid eye disease
Ophthalmology · 2025–2025
1decision
1medicine
1carried consumer input
11individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| teprotumumab Treatment of active, moderate-to-severe thyroid eye disease (TED). | May 2025 | Recommended with restriction | 11 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.